Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brimonidine.

L B Cantor1, J Burke

  • 1Indiana University Medical Center, Department of Ophthalmology, 702 Rotary Circle, Indianapolis, Indiana 46202, USA.

Expert Opinion on Investigational Drugs
|August 1, 1997
PubMed
Summary

Brimonidine tartrate effectively lowers intraocular pressure comparable to timolol and superior to betaxolol for glaucoma treatment. This alpha2-adrenergic agonist offers a safe alternative, especially for patients with cardiopulmonary risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fetal Alcohol Spectrum Disorder in Ireland.

Irish medical journal·2026
Same author

Correction: Measures of performance and proficiency in robotic assisted surgery: a systematic review.

Journal of robotic surgery·2025
Same author

Correction to: Measures of performance and proficiency in robotic assisted surgery: a systematic review.

Journal of robotic surgery·2024
Same author

Measures of performance and proficiency in robotic assisted surgery: a systematic review.

Journal of robotic surgery·2024
Same author

Animal factors that affect enteric methane production measured using the GreenFeed monitoring system in grazing dairy cows.

Journal of dairy science·2023
Same author

The Association of Surgeons in Training (ASiT) Consensus Statement on Major Trauma Training in the UK.

Annals of the Royal College of Surgeons of England·2023

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma is a leading cause of blindness globally, necessitating treatments to reduce intraocular pressure (IOP).
  • Beta-blockers are the current standard therapy for managing glaucoma and ocular hypertension.
  • Elevated IOP is a primary risk factor for glaucomatous optic neuropathy.

Purpose of the Study:

  • To evaluate the efficacy and safety of brimonidine tartrate as a treatment for glaucoma and ocular hypertension.
  • To compare the IOP-lowering effects of brimonidine tartrate with established therapies like timolol and betaxolol.

Main Methods:

  • Two 12-month clinical trials compared twice-daily brimonidine with twice-daily timolol (0.5%) in 926 patients.
  • A 3-month trial compared twice-daily brimonidine with twice-daily betaxolol (0.25% suspension) in 206 patients.

Main Results:

  • Brimonidine tartrate demonstrated comparable IOP reduction to timolol over 12 months.
  • Brimonidine tartrate showed superior IOP lowering compared to betaxolol over 3 months.
  • Brimonidine tartrate was well-tolerated systemically and ocularly, with no significant impact on heart rate, blood pressure, or FEV1.

Conclusions:

  • Brimonidine tartrate 0.2% twice daily is a clinically effective first-line therapy for glaucoma.
  • It serves as a safe and effective alternative to beta-blockers, particularly for patients with cardiovascular or pulmonary conditions.
  • Brimonidine tartrate reduces aqueous humor production and increases uveoscleral outflow, with potential neuroprotective properties requiring further investigation.

Related Experiment Videos